Virtual Library

Start Your Search

qiong He



Author of

  • +

    P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology (ID 153)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P14.15 - Circulating Tumor DNA Predict the Response and Survival after Tislelizumab Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma (ID 2443)

      00:00 - 00:00  |  Presenting Author(s): qiong He

      • Abstract
      • Slides

      Introduction

      Biomarkers are needed to identify patients at risk of tumor progression following immunotherapy (PD-1/PD-L1) and select the benefit patients for advanced esophageal squamous cell carcinoma (ESCC). These could improve identification of patients at risk for cancer progression and selection of therapy.

      Methods

      We collected endoscopic biopsy samples from 12 patients with ESCC who treated with Tislelizumab (an anti-PD-1 drug) every 3 weeks for a cycle. Plasma was collected before and after every 2-3 treatment cycle of Tislelizumab immunotherapy and when disease progression. We performed deep sequencing analyses of plasma cell-free DNA, as well as DNA from leukocytes, and fixed esophageal tumor biopsies. Patients were treated from May 2017 through Mar 2020. We analyzed 416 genes associated with ESCC. Patients underwent imaging analyses every 6–8 weeks after Tislelizumab immunotherapy until disease progression. Our primary aim was to determine whether detection and change of circulating tumor DNA (ctDNA) following Tislelizumab immunotherapy is associated with efficacy, risk of tumor progression and survival.

      Results

      All patients had evaluable NGS results at times of analysis. Using log-rank statistics, compared with wide type, JAK2-mutation patients showed significantly shorter progression-free survival (PFS) (13.17m vs. 2.5m log-rank test p<0.05). TSC2 mutation and KRAS amplication are the Independent and negative prognostic factors for esophageal squamous cell carcinoma who received Tislelizumab immunotherapy (OS: 13.17m vs. 17.6m p=0.0174; 11.72m vs.17.6m p=0.0123, independently). Down-regulation of Variant allele frequencies(dVAF)showed obviously longer PFS (13.17m vs. 3.45m p<0.0813) and OS (19.137m vs. 13.17m p=0.0575) without significant difference. At a certain extent, NGS analysis of ctDNA allows the prediction of tumor response and long-term clinical benefit with BGB-A317 in esophageal squamous cell carcinoma.

      Conclusion

      In an analysis of cell-free DNA in plasma samples from patients who underwent Tislelizumab immunotherapy for esophageal squamous cell carcinoma, detection of ctDNA was associated with anti-tumor effect, progression, and disease-specific survival. Analysis of ctDNA might be used to identify patients at risk for cancer progression and select suitable patients who received Tislelizumab immunotherapy.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.